{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:51:32Z","timestamp":1792086692432,"version":"4.4.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ogilvy Health UK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40263-025-01213-4","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T16:55:04Z","timestamp":1754585704000},"page":"1109-1138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8334-1403","authenticated-orcid":false,"given":"Kamil","family":"Detyniecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Roebling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Laloyaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Chanteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Cloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"6","key":"1213_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/nrl.0000000000000140","volume":"22","author":"PE Penovich","year":"2017","unstructured":"Penovich PE, Buelow J, Steinberg K, Sirven J, Wheless J. Burden of seizure clusters on patients with epilepsy and caregivers: survey of patient, caregiver, and clinician perspectives. Neurologist. 2017;22(6):207\u201314. https:\/\/doi.org\/10.1097\/nrl.0000000000000140.","journal-title":"Neurologist"},{"issue":"Suppl 10","key":"1213_CR2","first-page":"5","volume":"67","author":"GS Sachs","year":"2006","unstructured":"Sachs GS. A review of agitation in mental illness: burden of illness and underlying pathology. J Clin Psychiatry. 2006;67(Suppl 10):5\u201312.","journal-title":"J Clin Psychiatry"},{"issue":"12 Suppl","key":"1213_CR3","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.37765\/ajmc.2020.88517","volume":"26","author":"CM Tanner","year":"2020","unstructured":"Tanner CM. Exploring the clinical burden of OFF periods in Parkinson disease. Am J Manag Care. 2020;26(12 Suppl):S255\u201364. https:\/\/doi.org\/10.37765\/ajmc.2020.88517.","journal-title":"Am J Manag Care"},{"key":"1213_CR4","doi-asserted-by":"publisher","first-page":"1081757","DOI":"10.3389\/fepid.2023.1081757","volume":"3","author":"E Trinka","year":"2023","unstructured":"Trinka E, Rainer LJ, Granbichler CA, Zimmermann G, Leitinger M. Mortality, and life expectancy in epilepsy and status epilepticus\u2014current trends and future aspects. Front Epidemiol. 2023;3:1081757. https:\/\/doi.org\/10.3389\/fepid.2023.1081757.","journal-title":"Front Epidemiol"},{"issue":"1","key":"1213_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-024-01798-z","volume":"25","author":"J Cen","year":"2024","unstructured":"Cen J, Wang Q, Cheng L, Gao Q, Wang H, Sun F. Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the Global Burden of Disease Study 2021. J Headache Pain. 2024;25(1):96. https:\/\/doi.org\/10.1186\/s10194-024-01798-z.","journal-title":"J Headache Pain"},{"issue":"4","key":"1213_CR6","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/epd2.20243","volume":"26","author":"JE Pina-Garza","year":"2024","unstructured":"Pina-Garza JE, Chez M, Cloyd J, Hirsch LJ, K\u00e4lvi\u00e4inen R, Klein P, et al. Outpatient management of prolonged seizures and seizure clusters to prevent progression to a higher-level emergency: consensus recommendations of an expert working group. Epileptic Disord. 2024;26(4):484\u201397. https:\/\/doi.org\/10.1002\/epd2.20243.","journal-title":"Epileptic Disord"},{"issue":"8","key":"1213_CR7","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.3390\/jcm10081754","volume":"10","author":"S Almohaish","year":"2021","unstructured":"Almohaish S, Sandler M, Brophy GM. Time is brain: acute control of repetitive seizures and status epilepticus using alternative routes of administration of benzodiazepines. J Clin Med. 2021;10(8):1754. https:\/\/doi.org\/10.3390\/jcm10081754.","journal-title":"J Clin Med"},{"key":"1213_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2020.100409","volume":"15","author":"A Asnis-Alibozek","year":"2021","unstructured":"Asnis-Alibozek A, Detyniecki K. The unmet need for rapid epileptic seizure termination (REST). Epilepsy Behav Rep. 2021;15: 100409. https:\/\/doi.org\/10.1016\/j.ebr.2020.100409.","journal-title":"Epilepsy Behav Rep."},{"issue":"Suppl 2","key":"1213_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/epi.14479","volume":"59","author":"PD Maglalang","year":"2018","unstructured":"Maglalang PD, Rautiola D, Siegel RA, Fine JM, Hanson LR, Coles LD, et al. Rescue therapies for seizure emergencies: new modes of administration. Epilepsia. 2018;59(Suppl 2):207\u201315. https:\/\/doi.org\/10.1111\/epi.14479.","journal-title":"Epilepsia"},{"issue":"5","key":"1213_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/17425247.2022.2074975","volume":"19","author":"W Tai","year":"2022","unstructured":"Tai W, Kwok PCL. Recent advances in drug delivery to the central nervous system by inhalation. Expert Opin Drug Deliv. 2022;19(5):539\u201358. https:\/\/doi.org\/10.1080\/17425247.2022.2074975.","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"1213_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11684-012-0229-z","volume":"6","author":"C Zhou","year":"2012","unstructured":"Zhou C, Liu J. A novel intravenous general anesthetic\u2014emulsified isoflurane: from bench to bedside. Front Med. 2012;6(4):381\u20137. https:\/\/doi.org\/10.1007\/s11684-012-0229-z.","journal-title":"Front Med"},{"issue":"10","key":"1213_CR12","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.4088\/JCP.10m06011yel","volume":"72","author":"D Feifel","year":"2011","unstructured":"Feifel D, Allen MH, Lesem MD, Zimbroff DL, Ross R, Munzar P, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1313\u201321. https:\/\/doi.org\/10.4088\/JCP.10m06011yel.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1213_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1526-4610.2011.01869.x","volume":"51","author":"SK Aurora","year":"2011","unstructured":"Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51(4):507\u201317. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.01869.x.","journal-title":"Headache"},{"key":"1213_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/bs.pmch.2022.04.001","volume":"61","author":"W Czechtizky","year":"2022","unstructured":"Czechtizky W, Su W, Ripa L, Schiesser S, H\u00f6ijer A, Cox RJ. Advances in the design of new types of inhaled medicines. Prog Med Chem. 2022;61:93\u2013162. https:\/\/doi.org\/10.1016\/bs.pmch.2022.04.001.","journal-title":"Prog Med Chem"},{"issue":"2","key":"1213_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/epi.17441","volume":"64","author":"J French","year":"2023","unstructured":"French J, Biton V, Dave H, Detyniecki K, Gelfand MA, Gong H, et al. A randomized phase 2b efficacy study in patients with seizure episodes with a predictable pattern using Staccato\u00ae alprazolam for rapid seizure termination. Epilepsia. 2023;64(2):374\u201385. https:\/\/doi.org\/10.1111\/epi.17441.","journal-title":"Epilepsia"},{"issue":"3","key":"1213_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.2337\/diaspect.29.3.180","volume":"29","author":"J Oleck","year":"2016","unstructured":"Oleck J, Kassam S, Goldman JD. Commentary: why was inhaled insulin a failure in the market? Diabetes Spectr. 2016;29(3):180\u20134. https:\/\/doi.org\/10.2337\/diaspect.29.3.180.","journal-title":"Diabetes Spectr"},{"issue":"6","key":"1213_CR17","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.clinthera.2020.04.004","volume":"42","author":"BE Safirstein","year":"2020","unstructured":"Safirstein BE, Ellenbogen A, Zhao P, Henney HR 3rd, Kegler-Ebo DM, Oh C. Pharmacokinetics of inhaled levodopa administered with oral carbidopa in the fed state in patients with Parkinson\u2019s disease. Clin Ther. 2020;42(6):1034\u201346. https:\/\/doi.org\/10.1016\/j.clinthera.2020.04.004.","journal-title":"Clin Ther"},{"key":"1213_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.parkreldis.2022.02.014","volume":"97","author":"E Thijssen","year":"2022","unstructured":"Thijssen E, den Heijer JM, Puibert D, van Brummelen EMJ, Naranda T, Groeneveld GJ. Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson\u2019s disease patients. Parkinsonism Relat Disord. 2022;97:84\u201390. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.02.014.","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"1213_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/17460441.2019.1598373","volume":"14","author":"N Vandenbussche","year":"2019","unstructured":"Vandenbussche N, Goadsby PJ. The discovery and development of inhaled therapeutics for migraine. Expert Opin Drug Discov. 2019;14(6):591\u20139. https:\/\/doi.org\/10.1080\/17460441.2019.1598373.","journal-title":"Expert Opin Drug Discov"},{"key":"1213_CR20","unstructured":"Acorda Therapeutics Ireland Limited. INBRIJA summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inbrija-epar-product-information_en.pdf. Accessed 2 Dec 2024."},{"key":"1213_CR21","unstructured":"Ferrer Internacional, S.A. ADASUVE summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adasuve-epar-product-information_en.pdf. Accessed 2 Dec 2024."},{"issue":"2","key":"1213_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/0091270012436886","volume":"53","author":"MJ Avram","year":"2013","unstructured":"Avram MJ, Spyker DA, Kehne JH, Cassella JV. The pharmacokinetics and pharmacodynamics of zaleplon delivered as a thermally generated aerosol in a single breath to volunteers. J Clin Pharmacol. 2013;53(2):140\u201350. https:\/\/doi.org\/10.1177\/0091270012436886.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1213_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/epi.17901","volume":"65","author":"Y Hayakawa","year":"2024","unstructured":"Hayakawa Y, Rospo C, Bartmann AP, King A, Roebling R, Chanteux H. Pharmacokinetics of Staccato\u00ae alprazolam in healthy adult participants in two phase 1 studies: an open-label smoker study and a randomized, placebo-controlled ethnobridging study. Epilepsia. 2024;65(4):887\u201399. https:\/\/doi.org\/10.1111\/epi.17901.","journal-title":"Epilepsia"},{"issue":"1","key":"1213_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1526-4610.2011.02041.x","volume":"52","author":"SJ Tepper","year":"2012","unstructured":"Tepper SJ, Kori SH, Borland SW, Wang MH, Hu B, Mathew NT, et al. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache. 2012;52(1):37\u201347. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.02041.x.","journal-title":"Headache"},{"key":"1213_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2022.102127","volume":"73","author":"M Mat\u0142oka","year":"2022","unstructured":"Mat\u0142oka M, Janowska S, Gajos-Draus A, Zi\u00f3\u0142kowski H, Janicka M, Perko P, et al. Esketamine inhaled as dry powder: pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study. Pulm Pharmacol Ther. 2022;73: 102127. https:\/\/doi.org\/10.1016\/j.pupt.2022.102127.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"1213_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/head.13700","volume":"60","author":"SD Silberstein","year":"2020","unstructured":"Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE)\u2014then and now: a narrative review. Headache. 2020;60(1):40\u201357. https:\/\/doi.org\/10.1111\/head.13700.","journal-title":"Headache"},{"issue":"8","key":"1213_CR27","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/epi.16279","volume":"60","author":"JA French","year":"2019","unstructured":"French JA, Wechsler R, Gelfand MA, Pollard JR, Vazquez B, Friedman D, et al. Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants. Epilepsia. 2019;60(8):1602\u20139. https:\/\/doi.org\/10.1111\/epi.16279.","journal-title":"Epilepsia"},{"issue":"1","key":"1213_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1192\/bjp.bp.110.081513","volume":"198","author":"MD Lesem","year":"2011","unstructured":"Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198(1):51\u20138. https:\/\/doi.org\/10.1192\/bjp.bp.110.081513.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"1213_CR29","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.euroneuro.2018.03.010","volume":"28","author":"L San","year":"2018","unstructured":"San L, Estrada G, Oudovenko N, Monta\u00f1\u00e9s F, Dobrovolskaya N, Bukhanovskaya O, et al. PLACID study: a randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. Eur Neuropsychopharmacol. 2018;28(6):710\u20138. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.03.010.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"1213_CR30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/jamp.2013.1114","volume":"27","author":"N Gross","year":"2014","unstructured":"Gross N, Greos LS, Meltzer EO, Spangenthal S, Fishman RS, Spyker DA, et al. Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease\u2014two randomized controlled trials. J Aerosol Med Pulm Drug Deliv. 2014;27(6):478\u201387. https:\/\/doi.org\/10.1089\/jamp.2013.1114.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"1213_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","volume":"37","author":"KD Laxer","year":"2014","unstructured":"Laxer KD, Trinka E, Hirsch LJ, Cendes F, Langfitt J, Delanty N, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59\u201370. https:\/\/doi.org\/10.1016\/j.yebeh.2014.05.031.","journal-title":"Epilepsy Behav"},{"key":"1213_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.seizure.2024.04.005","volume":"118","author":"M Maltseva","year":"2024","unstructured":"Maltseva M, Rosenow F, von Podewils F, Habermehl L, Langenbruch L, Bierhansl L, et al. Predictors for and use of rescue medication in adults with epilepsy: a multicentre cross-sectional study from Germany. Seizure. 2024;118:58\u201364. https:\/\/doi.org\/10.1016\/j.seizure.2024.04.005.","journal-title":"Seizure"},{"issue":"8","key":"1213_CR33","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40263-018-0544-2","volume":"32","author":"J Kadel","year":"2018","unstructured":"Kadel J, Bauer S, Hermsen AM, Immisch I, Kay L, Klein KM, et al. Use of emergency medication in adult patients with epilepsy: a multicentre cohort study from Germany. CNS Drugs. 2018;32(8):771\u201381. https:\/\/doi.org\/10.1007\/s40263-018-0544-2.","journal-title":"CNS Drugs"},{"issue":"9","key":"1213_CR34","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","volume":"36","author":"R Kienitz","year":"2022","unstructured":"Kienitz R, Kay L, Beuchat I, Gelhard S, von Brauchitsch S, Mann C, et al. Benzodiazepines in the management of seizures and status epilepticus: a review of routes of delivery, pharmacokinetics, efficacy, and tolerability. CNS Drugs. 2022;36(9):951\u201375. https:\/\/doi.org\/10.1007\/s40263-022-00940-2.","journal-title":"CNS Drugs"},{"issue":"9","key":"1213_CR35","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3390\/pharmaceutics14091974","volume":"14","author":"YB Zhang","year":"2022","unstructured":"Zhang YB, Xu D, Bai L, Zhou YM, Zhang H, Cui YL. A review of non-invasive drug delivery through respiratory routes. Pharmaceutics. 2022;14(9):1974. https:\/\/doi.org\/10.3390\/pharmaceutics14091974.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1213_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","volume":"74","author":"S Anderson","year":"2022","unstructured":"Anderson S, Atkins P, B\u00e4ckman P, Cipolla D, Clark A, Daviskas E, et al. Inhaled medicines: past, present, and future. Pharmacol Rev. 2022;74(1):48\u2013118. https:\/\/doi.org\/10.1124\/pharmrev.120.000108.","journal-title":"Pharmacol Rev"},{"key":"1213_CR37","doi-asserted-by":"publisher","first-page":"2732017","DOI":"10.1155\/2018\/2732017","volume":"2018","author":"JM Borghardt","year":"2018","unstructured":"Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can Respir J. 2018;2018:2732017. https:\/\/doi.org\/10.1155\/2018\/2732017.","journal-title":"Can Respir J"},{"key":"1213_CR38","unstructured":"Leone-Bay A, Baughman R, Smutney C, Kocinsky J. Innovation in drug delivery by inhalation. In: ONdrugDelivery. Frederick Furness Publishing. 2010. https:\/\/www.ondrugdelivery.com\/wp-content\/uploads\/2018\/11\/Nov2010.pdf. Accessed 28 Nov 2024."},{"issue":"9\u201310","key":"1213_CR39","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.addr.2006.07.009","volume":"58","author":"G Scheuch","year":"2006","unstructured":"Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev. 2006;58(9\u201310):996\u20131008. https:\/\/doi.org\/10.1016\/j.addr.2006.07.009.","journal-title":"Adv Drug Deliv Rev"},{"key":"1213_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fneng.2013.00007","volume":"6","author":"AD Wong","year":"2013","unstructured":"Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE, Searson PC. The blood\u2013brain barrier: an engineering perspective. Front Neuroeng. 2013;6: 7. https:\/\/doi.org\/10.3389\/fneng.2013.00007.","journal-title":"Front Neuroeng"},{"issue":"1","key":"1213_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrd2153","volume":"6","author":"JS Patton","year":"2007","unstructured":"Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67\u201374. https:\/\/doi.org\/10.1038\/nrd2153.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1213_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/jam.1994.7.49","volume":"7","author":"PR Byron","year":"1994","unstructured":"Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med. 1994;7(1):49\u201375. https:\/\/doi.org\/10.1089\/jam.1994.7.49.","journal-title":"J Aerosol Med"},{"issue":"6","key":"1213_CR43","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","volume":"56","author":"NR Labiris","year":"2003","unstructured":"Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588\u201399. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01892.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1213_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.dmpk.2015.11.006","volume":"31","author":"Y Tega","year":"2016","unstructured":"Tega Y, Yuzurihara C, Kubo Y, Akanuma SI, Ehrhardt C, Hosoya KI. Functional expression of nicotine influx transporter in A549 human alveolar epithelial cells. Drug Metab Pharmacokinet. 2016;31(1):99\u2013101. https:\/\/doi.org\/10.1016\/j.dmpk.2015.11.006.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"1213_CR45","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.bbamem.2009.03.003","volume":"1788","author":"S Seki","year":"2009","unstructured":"Seki S, Kobayashi M, Itagaki S, Hirano T, Iseki K. Contribution of organic anion transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells. Biochim Biophys Acta. 2009;1788(5):911\u20137. https:\/\/doi.org\/10.1016\/j.bbamem.2009.03.003.","journal-title":"Biochim Biophys Acta"},{"key":"1213_CR46","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3389\/fbioe.2020.01030","volume":"8","author":"MA Selo","year":"2020","unstructured":"Selo MA, Delmas AS, Springer L, Zoufal V, Sake JA, Clerkin CG, et al. Tobacco smoke and inhaled drugs alter expression and activity of multidrug resistance-associated protein-1 (MRP1) in human distal lung epithelial cells in vitro. Front Bioeng Biotechnol. 2020;8:1030. https:\/\/doi.org\/10.3389\/fbioe.2020.01030.","journal-title":"Front Bioeng Biotechnol"},{"issue":"Pt 4","key":"1213_CR47","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1113\/jphysiol.2010.204776","volume":"589","author":"CK Willie","year":"2011","unstructured":"Willie CK, Smith KJ. Fuelling the exercising brain: a regulatory quagmire for lactate metabolism. J Physiol. 2011;589(Pt 4):779\u201380. https:\/\/doi.org\/10.1113\/jphysiol.2010.204776.","journal-title":"J Physiol"},{"issue":"4","key":"1213_CR48","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/j.1476-5381.2009.00624.x","volume":"160","author":"ES Vizi","year":"2010","unstructured":"Vizi ES, Fekete A, Karoly R, Mike A. Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment. Br J Pharmacol. 2010;160(4):785\u2013809. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00624.x.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1213_CR49","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"H Pajouhesh","year":"2005","unstructured":"Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005;2(4):541\u201353. https:\/\/doi.org\/10.1602\/neurorx.2.4.541.","journal-title":"NeuroRx"},{"issue":"9","key":"1213_CR50","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.4155\/tde.11.90","volume":"2","author":"P Noymer","year":"2011","unstructured":"Noymer P, Biondi S, Myers D, Cassella J. Pulmonary delivery of therapeutic compounds for treating CNS disorders. Ther Deliv. 2011;2(9):1125\u201340. https:\/\/doi.org\/10.4155\/tde.11.90.","journal-title":"Ther Deliv"},{"key":"1213_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","volume":"237","author":"M Kapoor","year":"2016","unstructured":"Kapoor M, Cloyd JC, Siegel RA. A review of intranasal formulations for the treatment of seizure emergencies. J Control Release. 2016;237:147\u201359. https:\/\/doi.org\/10.1016\/j.jconrel.2016.07.001.","journal-title":"J Control Release"},{"key":"1213_CR52","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3389\/fphar.2019.01328","volume":"10","author":"S Hua","year":"2019","unstructured":"Hua S. Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration. Front Pharmacol. 2019;10:1328. https:\/\/doi.org\/10.3389\/fphar.2019.01328.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1213_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/jamp.2016.1297","volume":"30","author":"SW Stein","year":"2017","unstructured":"Stein SW, Thiel CG. The history of therapeutic aerosols: a chronological review. J Aerosol Med Pulm Drug Deliv. 2017;30(1):20\u201341. https:\/\/doi.org\/10.1089\/jamp.2016.1297.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"10","key":"1213_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12100911","volume":"12","author":"A Y\u0131ld\u0131z-Pek\u00f6z","year":"2020","unstructured":"Y\u0131ld\u0131z-Pek\u00f6z A, Ehrhardt C. Advances in pulmonary drug delivery. Pharmaceutics. 2020;12(10): 911. https:\/\/doi.org\/10.3390\/pharmaceutics12100911.","journal-title":"Pharmaceutics"},{"key":"1213_CR55","doi-asserted-by":"crossref","unstructured":"Shehata M. History of inhalation therapy. In: Internet Journal of Health. Internet Scientific Publications. 2008. https:\/\/ispub.com\/IJH\/9\/1\/7338. Accessed 28 Nov 2024.","DOI":"10.5580\/10d8"},{"issue":"2","key":"1213_CR56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3132\/pcrj.2007.00017","volume":"16","author":"M Sanders","year":"2007","unstructured":"Sanders M. Inhalation therapy: an historical review. Prim Care Respir J. 2007;16(2):71\u201381. https:\/\/doi.org\/10.3132\/pcrj.2007.00017.","journal-title":"Prim Care Respir J"},{"issue":"3","key":"1213_CR57","first-page":"182","volume":"5","author":"S Mahdizadeh","year":"2015","unstructured":"Mahdizadeh S, Khaleghi Ghadiri M, Gorji A. Avicenna\u2019s Canon of Medicine: a review of analgesics and anti-inflammatory substances. Avicenna J Phytomed. 2015;5(3):182\u2013202.","journal-title":"Avicenna J Phytomed"},{"issue":"1","key":"1213_CR58","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/08998280.2006.11928120","volume":"19","author":"MAE Ramsay","year":"2006","unstructured":"Ramsay MAE. John Snow, MD: anaesthetist to the Queen of England and pioneer epidemiologist. Proc (Bayl Univ Med Cent). 2006;19(1):24\u20138. https:\/\/doi.org\/10.1080\/08998280.2006.11928120.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"6","key":"1213_CR59","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1046\/j.1365-2125.2003.01893.x","volume":"56","author":"NR Labiris","year":"2003","unstructured":"Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):600\u201312. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01893.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1213_CR60","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/B978-0-323-46143-6.00022-1","volume-title":"Nanostructures for drug delivery","author":"AK Goyal","year":"2017","unstructured":"Goyal AK, Garg T, Bhandari S, Rath G. Advancement in pulmonary drug delivery systems for treatment of tuberculosis. In: Andronescu E, Grumezescu AM, editors. Nanostructures for drug delivery. Amsterdam: Elsevier; 2017. p. 669\u201395."},{"issue":"9","key":"1213_CR61","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.4187\/respcare.05501139","volume":"50","author":"PJ Anderson","year":"2005","unstructured":"Anderson PJ. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir Care. 2005;50(9):1139\u201350.","journal-title":"Respir Care"},{"issue":"5","key":"1213_CR62","first-page":"264","volume":"2","author":"N Islam","year":"2008","unstructured":"Islam N, Rahman S. Pulmonary drug delivery: implication for new strategy for pharmacotherapy for neurodegenerative disorders. Drug Discov Ther. 2008;2(5):264\u201376.","journal-title":"Drug Discov Ther"},{"issue":"5","key":"1213_CR63","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jaip.2016.03.002","volume":"4","author":"F Braido","year":"2016","unstructured":"Braido F, Chrystyn H, Baiardini I, Bosnic-Anticevich S, van der Molen T, Dandurand RJ, et al. Trying, but failing\u2014the role of inhaler technique and mode of delivery in respiratory medication adherence. J Allergy Clin Immunol Pract. 2016;4(5):823\u201332. https:\/\/doi.org\/10.1016\/j.jaip.2016.03.002.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"1213_CR64","doi-asserted-by":"publisher","DOI":"10.1088\/1752-7163\/acc8f1","volume":"17","author":"MD Davis","year":"2023","unstructured":"Davis MD, Saunders JL, Ringer C, Engberg R, Zhao Y, DiBlasi RM, et al. In vitro-in vivo correlation of aerosol deposition before and after metered-dose inhaler coaching in healthy children. J Breath Res. 2023;17(3): 036002. https:\/\/doi.org\/10.1088\/1752-7163\/acc8f1.","journal-title":"J Breath Res"},{"issue":"1\u20132","key":"1213_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","volume":"392","author":"G Pilcer","year":"2010","unstructured":"Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1\u20132):1\u201319. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.03.017.","journal-title":"Int J Pharm"},{"issue":"2","key":"1213_CR66","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/s1474-4422(18)30405-8","volume":"18","author":"PA LeWitt","year":"2019","unstructured":"LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18(2):145\u201354. https:\/\/doi.org\/10.1016\/s1474-4422(18)30405-8.","journal-title":"Lancet Neurol"},{"key":"1213_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121457","volume":"614","author":"Y Ye","year":"2022","unstructured":"Ye Y, Ma Y, Zhu J. The future of dry powder inhaled therapy: promising or discouraging for systemic disorders? Int J Pharm. 2022;614:121457. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121457.","journal-title":"Int J Pharm"},{"issue":"9","key":"1213_CR68","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.3390\/pharmaceutics13091528","volume":"13","author":"YJ Son","year":"2021","unstructured":"Son YJ, Miller DP, Weers JG. Optimizing spray-dried porous particles for high dose delivery with a portable dry powder inhaler. Pharmaceutics. 2021;13(9):1528. https:\/\/doi.org\/10.3390\/pharmaceutics13091528.","journal-title":"Pharmaceutics"},{"key":"1213_CR69","unstructured":"Watts A. ARCUS\u00ae: a commercialised technology enabling high-dose, highly respirable powders. In: ONdrugDelivery. Frederick Furness Publishing. 2024. https:\/\/www.ondrugdelivery.com\/wp-content\/uploads\/2024\/04\/158_2024_Apr_Pulmonary_Nasal_Catalent_Acorda.pdf. Accessed 28 Nov 2024."},{"key":"1213_CR70","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.addr.2014.04.005","volume":"75","author":"AM Healy","year":"2014","unstructured":"Healy AM, Amaro MI, Paluch KJ, Tajber L. Dry powders for oral inhalation free of lactose carrier particles. Adv Drug Deliv Rev. 2014;75:32\u201352. https:\/\/doi.org\/10.1016\/j.addr.2014.04.005.","journal-title":"Adv Drug Deliv Rev"},{"key":"1213_CR71","unstructured":"Ferrer.com. Pipeline. Ferrer. 2024. https:\/\/ferrer.com\/en\/science\/r-d-strategy#pipeline. Accessed 2 Dec 2024."},{"key":"1213_CR72","unstructured":"Staccatoobt.com. Unleash the speed of Staccato\u00ae One Breath Technology\u2122 \u2013 OBT\u2122. Alexza Ferrer. 2019. https:\/\/staccatoobt.com\/. Accessed 02 Dec 2024."},{"issue":"9","key":"1213_CR73","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/03639040802149061","volume":"34","author":"K Simis","year":"2008","unstructured":"Simis K, Lei M, Lu AT, Sharma KC, Hale RL, Timmons R, et al. Nicotine aerosol generation from thermally reversible zinc halide complexes using the Staccato system. Drug Dev Ind Pharm. 2008;34(9):936\u201342. https:\/\/doi.org\/10.1080\/03639040802149061.","journal-title":"Drug Dev Ind Pharm"},{"issue":"4","key":"1213_CR74","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1089\/jamp.2009.0814","volume":"23","author":"KV Dinh","year":"2010","unstructured":"Dinh KV, Myers DJ, Noymer PD, Cassella JV. In vitro aerosol deposition in the oropharyngeal region for Staccato loxapine. J Aerosol Med Pulm Drug Deliv. 2010;23(4):253\u201360. https:\/\/doi.org\/10.1089\/jamp.2009.0814.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"3","key":"1213_CR75","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1742-1241.2010.02615.x","volume":"65","author":"L Citrome","year":"2011","unstructured":"Citrome L. Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. Int J Clin Pract. 2011;65(3):330\u201340. https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02615.x.","journal-title":"Int J Clin Pract"},{"issue":"24","key":"1213_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28248038","volume":"28","author":"M Stielow","year":"2023","unstructured":"Stielow M, Witczy\u0144ska A, Kubry\u0144 N, Fija\u0142kowski \u0141, Nowaczyk J, Nowaczyk A. The bioavailability of drugs\u2014the current state of knowledge. Molecules. 2023;28(24): 8038. https:\/\/doi.org\/10.3390\/molecules28248038.","journal-title":"Molecules"},{"issue":"3","key":"1213_CR77","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2967\/jnmt.117.199638","volume":"46","author":"GM Currie","year":"2018","unstructured":"Currie GM. Pharmacology, part 2: introduction to pharmacokinetics. J Nucl Med Technol. 2018;46(3):221\u201330. https:\/\/doi.org\/10.2967\/jnmt.117.199638.","journal-title":"J Nucl Med Technol"},{"issue":"2","key":"1213_CR78","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/chir.23148","volume":"32","author":"A Matji","year":"2020","unstructured":"Matji A, Vargas E, Carvajal L, Terleira AI, Portol\u00e9s A, Garcia-Arieta A, et al. Effect of enantiomerism on the bioequivalence of a new ibuprofen 600-mg tablet formulation obtained by roller compaction. Chirality. 2020;32(2):185\u201390. https:\/\/doi.org\/10.1002\/chir.23148.","journal-title":"Chirality"},{"key":"1213_CR79","volume-title":"Fundamentals of toxicology: essential concepts and applications","author":"PK Gupta","year":"2016","unstructured":"Gupta PK. Fundamentals of toxicology: essential concepts and applications. Cambridge: Academic; 2016."},{"issue":"1","key":"1213_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","volume":"24","author":"JS Kang","year":"2009","unstructured":"Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1\u201310. https:\/\/doi.org\/10.3904\/kjim.2009.24.1.1.","journal-title":"Korean J Intern Med"},{"issue":"12","key":"1213_CR81","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/acn3.50932","volume":"6","author":"L Kay","year":"2019","unstructured":"Kay L, Merkel N, von Blomberg A, Willems LM, Bauer S, Reif PS, et al. Intranasal midazolam as first-line inhospital treatment for status epilepticus: a pharmaco-EEG cohort study. Ann Clin Transl Neurol. 2019;6(12):2413\u201325. https:\/\/doi.org\/10.1002\/acn3.50932.","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"1213_CR82","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/clpt.2011.316","volume":"91","author":"M Hardmeier","year":"2012","unstructured":"Hardmeier M, Zimmermann R, R\u00fcegg S, Pfl\u00fcger M, Deuster S, Suter K, et al. Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. Clin Pharmacol Ther. 2012;91(5):856\u201362. https:\/\/doi.org\/10.1038\/clpt.2011.316.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 8","key":"1213_CR83","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1528-1167.2011.03235.x","volume":"52","author":"R Silbergleit","year":"2011","unstructured":"Silbergleit R, Lowenstein D, Durkalski V, Conwit R. RAMPART (rapid anticonvulsant medication prior to arrival trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia. 2011;52(Suppl 8):45\u20137. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03235.x.","journal-title":"Epilepsia"},{"issue":"2","key":"1213_CR84","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40263-023-01060-1","volume":"38","author":"PE Penovich","year":"2024","unstructured":"Penovich PE, Rao VR, Long L, Carrazana E, Rabinowicz AL. Benzodiazepines for the treatment of seizure clusters. CNS Drugs. 2024;38(2):125\u201340. https:\/\/doi.org\/10.1007\/s40263-023-01060-1.","journal-title":"CNS Drugs"},{"issue":"15","key":"1213_CR85","doi-asserted-by":"publisher","first-page":"437","DOI":"10.15585\/mmwr.mm6715a1","volume":"67","author":"N Tian","year":"2018","unstructured":"Tian N, Boring M, Kobau R, Zack MM, Croft JB. Active epilepsy and seizure control in adults\u2014United States, 2013 and 2015. MMWR Morb Mortal Wkly Rep. 2018;67(15):437\u201342. https:\/\/doi.org\/10.15585\/mmwr.mm6715a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"1213_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020242","volume":"8","author":"E Gil","year":"2018","unstructured":"Gil E, Garcia-Alonso F, Boldeanu A, Baleeiro Teixeira T. Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial. BMJ Open. 2018;8(10): e020242. https:\/\/doi.org\/10.1136\/bmjopen-2017-020242.","journal-title":"BMJ Open"},{"key":"1213_CR87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12991-015-0053-3","volume":"14","author":"D Popovic","year":"2015","unstructured":"Popovic D, Nuss P, Vieta E. Revisiting loxapine: a systematic review. Ann Gen Psychiatry. 2015;14:15. https:\/\/doi.org\/10.1186\/s12991-015-0053-3.","journal-title":"Ann Gen Psychiatry"},{"issue":"2","key":"1213_CR88","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/0091270009347866","volume":"50","author":"DA Spyker","year":"2010","unstructured":"Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol. 2010;50(2):169\u201379. https:\/\/doi.org\/10.1177\/0091270009347866.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1213_CR89","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/jcph.502","volume":"55","author":"DA Spyker","year":"2015","unstructured":"Spyker DA, Riesenberg RA, Cassella JV. Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens. J Clin Pharmacol. 2015;55(9):985\u201394. https:\/\/doi.org\/10.1002\/jcph.502.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1213_CR90","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/bf00431855","volume":"56","author":"GM Simpson","year":"1978","unstructured":"Simpson GM, Cooper TB, Lee JH, Young MA. Clinical and plasma level characteristics of intramuscular and oral loxapine. Psychopharmacology. 1978;56(2):225\u201332. https:\/\/doi.org\/10.1007\/bf00431855.","journal-title":"Psychopharmacology"},{"issue":"360","key":"1213_CR91","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad8858","volume":"8","author":"MM Lipp","year":"2016","unstructured":"Lipp MM, Batycky R, Moore J, Leinonen M, Freed MI. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson\u2019s disease. Sci Transl Med. 2016;8(360): 360ra136. https:\/\/doi.org\/10.1126\/scitranslmed.aad8858.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1213_CR92","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"PA LeWitt","year":"2015","unstructured":"LeWitt PA. Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64\u201372. https:\/\/doi.org\/10.1002\/mds.26082.","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"1213_CR93","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jns.2012.05.010","volume":"319","author":"H Doi","year":"2012","unstructured":"Doi H, Sakakibara R, Sato M, Masaka T, Kishi M, Tateno A, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson\u2019s disease. J Neurol Sci. 2012;319(1\u20132):86\u20138. https:\/\/doi.org\/10.1016\/j.jns.2012.05.010.","journal-title":"J Neurol Sci"},{"issue":"8","key":"1213_CR94","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2174\/1570159x15666170510143821","volume":"16","author":"N Tambasco","year":"2018","unstructured":"Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson\u2019s disease: current status and future developments. Curr Neuropharmacol. 2018;16(8):1239\u201352. https:\/\/doi.org\/10.2174\/1570159x15666170510143821.","journal-title":"Curr Neuropharmacol"},{"issue":"11","key":"1213_CR95","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1080\/17425247.2021.1960820","volume":"18","author":"MM Lipp","year":"2021","unstructured":"Lipp MM, Hickey AJ, Langer R, LeWitt PA. A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson\u2019s disease. Expert Opin Drug Deliv. 2021;18(11):1559\u201369. https:\/\/doi.org\/10.1080\/17425247.2021.1960820.","journal-title":"Expert Opin Drug Deliv"},{"issue":"Pt A","key":"1213_CR96","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejpb.2015.10.003","volume":"97","author":"M Luinstra","year":"2015","unstructured":"Luinstra M, Grasmeijer F, Hagedoorn P, Moes JR, Frijlink HW, de Boer AH. A levodopa dry powder inhaler for the treatment of Parkinson\u2019s disease patients in off periods. Eur J Pharm Biopharm. 2015;97(Pt A):22\u20139. https:\/\/doi.org\/10.1016\/j.ejpb.2015.10.003.","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"1213_CR97","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/00325481.2021.1936087","volume":"133","author":"RA Hauser","year":"2021","unstructured":"Hauser RA, LeWitt PA, Comella CL. On demand therapy for Parkinson\u2019s disease patients: opportunities and choices. Postgrad Med. 2021;133(7):721\u20137. https:\/\/doi.org\/10.1080\/00325481.2021.1936087.","journal-title":"Postgrad Med"},{"key":"1213_CR98","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319857617","volume":"10","author":"M Luinstra","year":"2019","unstructured":"Luinstra M, Rutgers W, van Laar T, Grasmeijer F, Begeman A, Isufi V, et al. Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson\u2019s disease. Ther Adv Chronic Dis. 2019;10: 2040622319857617. https:\/\/doi.org\/10.1177\/2040622319857617.","journal-title":"Ther Adv Chronic Dis"},{"issue":"11","key":"1213_CR99","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1007\/s00415-020-10031-1","volume":"267","author":"P Hagell","year":"2020","unstructured":"Hagell P, H\u00f6glund A, Hellqvist C, Johansson EL, L\u00f6wed B, Sj\u00f6str\u00f6m AC, et al. Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson\u2019s disease. J Neurol. 2020;267(11):3411\u20137. https:\/\/doi.org\/10.1007\/s00415-020-10031-1.","journal-title":"J Neurol"},{"issue":"4","key":"1213_CR100","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/cts.13008","volume":"14","author":"F Agbo","year":"2021","unstructured":"Agbo F, Crass RL, Chiu YY, Chapel S, Galluppi G, Blum D, et al. Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson\u2019s disease. Clin Transl Sci. 2021;14(4):1464\u201375. https:\/\/doi.org\/10.1111\/cts.13008.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1213_CR101","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/jpd-120142","volume":"3","author":"KA Grosset","year":"2013","unstructured":"Grosset KA, Malek N, Morgan F, Grosset DG. Inhaled apomorphine in patients with \u201con\u2013off\u201d fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study. J Parkinsons Dis. 2013;3(1):31\u20137. https:\/\/doi.org\/10.3233\/jpd-120142.","journal-title":"J Parkinsons Dis"},{"issue":"9","key":"1213_CR102","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","volume":"33","author":"F Carbone","year":"2019","unstructured":"Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson\u2019s disease: efficacy and safety of current and new formulations. CNS Drugs. 2019;33(9):905\u201318. https:\/\/doi.org\/10.1007\/s40263-019-00661-z.","journal-title":"CNS Drugs"},{"issue":"11","key":"1213_CR103","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/ene.12091","volume":"20","author":"KA Grosset","year":"2013","unstructured":"Grosset KA, Malek N, Morgan F, Grosset DG. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing \u201coff\u201d periods in patients with established Parkinson\u2019s disease. Eur J Neurol. 2013;20(11):1445\u201350. https:\/\/doi.org\/10.1111\/ene.12091.","journal-title":"Eur J Neurol"},{"issue":"3","key":"1213_CR104","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/ane.12107","volume":"128","author":"KA Grosset","year":"2013","unstructured":"Grosset KA, Malek N, Morgan F, Grosset DG. Inhaled dry powder apomorphine (VR040) for \u201coff\u201d periods in Parkinson\u2019s disease: an in-clinic double-blind dose ranging study. Acta Neurol Scand. 2013;128(3):166\u201371. https:\/\/doi.org\/10.1111\/ane.12107.","journal-title":"Acta Neurol Scand"},{"issue":"Spec No 1","key":"1213_CR105","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1684\/epd.2014.0691","volume":"16","author":"DE Naylor","year":"2014","unstructured":"Naylor DE. Treating acute seizures with benzodiazepines: does seizure duration matter? Epileptic Disord. 2014;16(Spec No 1):S69-83. https:\/\/doi.org\/10.1684\/epd.2014.0691.","journal-title":"Epileptic Disord"},{"issue":"5 Suppl","key":"1213_CR106","doi-asserted-by":"publisher","first-page":"14S","DOI":"10.1177\/0883073807303065","volume":"22","author":"S Shinnar","year":"2007","unstructured":"Shinnar S. Who is at risk for prolonged seizures? J Child Neurol. 2007;22(5 Suppl):14S-20S. https:\/\/doi.org\/10.1177\/0883073807303065.","journal-title":"J Child Neurol"},{"key":"1213_CR107","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fneur.2017.00507","volume":"8","author":"LM Kortland","year":"2017","unstructured":"Kortland LM, Knake S, von Podewils F, Rosenow F, Strzelczyk A. Socioeconomic outcome and quality of life in adults after status epilepticus: a multicenter, longitudinal, matched case-control analysis from Germany. Front Neurol. 2017;8:507. https:\/\/doi.org\/10.3389\/fneur.2017.00507.","journal-title":"Front Neurol"},{"issue":"Pt A","key":"1213_CR108","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.yebeh.2017.02.023","volume":"71","author":"AK Berg","year":"2017","unstructured":"Berg AK, Myrvik MJ, Van Ess PJ. Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: randomized study in healthy geriatric and non-geriatric adults. Epilepsy Behav. 2017;71(Pt A):51\u20139. https:\/\/doi.org\/10.1016\/j.yebeh.2017.02.023.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"1213_CR109","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.1365-2125.1998.00781.x","volume":"46","author":"R Schwagmeier","year":"1998","unstructured":"Schwagmeier R, Alincic S, Striebel HW. Midazolam pharmacokinetics following intravenous and buccal administration. Br J Clin Pharmacol. 1998;46(3):203\u20136. https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00781.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1213_CR110","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40120-024-00627-4","volume":"13","author":"O Lacombe","year":"2024","unstructured":"Lacombe O, Pletan Y, Grouin JM, Brennan A, Gir\u00e9 O. Relative bioavailability study of midazolam intramuscularly administered with the needle-free auto-injector ZENEO\u00ae in healthy adults. Neurol Ther. 2024;13(4):1155\u201372. https:\/\/doi.org\/10.1007\/s40120-024-00627-4.","journal-title":"Neurol Ther"},{"issue":"3","key":"1213_CR111","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/epi.16449","volume":"61","author":"RE Hogan","year":"2020","unstructured":"Hogan RE, Gidal BE, Koplowitz B, Koplowitz LP, Lowenthal RE, Carrazana E. Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers. Epilepsia. 2020;61(3):455\u201364. https:\/\/doi.org\/10.1111\/epi.16449.","journal-title":"Epilepsia"},{"issue":"Pt B","key":"1213_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106537","volume":"101","author":"MA Rogawski","year":"2019","unstructured":"Rogawski MA, Heller AH. Diazepam buccal film for the treatment of acute seizures. Epilepsy Behav. 2019;101(Pt B): 106537. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106537.","journal-title":"Epilepsy Behav"},{"issue":"5","key":"1213_CR113","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1528-1157.1998.tb01415.x","volume":"39","author":"JC Cloyd","year":"1998","unstructured":"Cloyd JC, Lalonde RL, Beniak TE, Novack GD. A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam. Epilepsia. 1998;39(5):520\u20136. https:\/\/doi.org\/10.1111\/j.1528-1157.1998.tb01415.x.","journal-title":"Epilepsia"},{"key":"1213_CR114","unstructured":"Greenwich Biosciences. EPIDIOLEX prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf. Accessed 2 Dec 2024."},{"issue":"12","key":"1213_CR115","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1016\/j.xphs.2021.08.012","volume":"110","author":"O Devinsky","year":"2021","unstructured":"Devinsky O, Kraft K, Rusch L, Fein M, Leone-Bay A. Improved bioavailability with dry powder cannabidiol inhalation: a phase 1 clinical study. J Pharm Sci. 2021;110(12):3946\u201352. https:\/\/doi.org\/10.1016\/j.xphs.2021.08.012.","journal-title":"J Pharm Sci"},{"issue":"5","key":"1213_CR116","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1089\/jamp.2012.0999","volume":"26","author":"DJ Kellerman","year":"2013","unstructured":"Kellerman DJ, Forst A, Combs DL, Borland S, Kori S. Assessment of the consistency of absorption of dihydroergotamine following oral inhalation: pooled results from four clinical studies. J Aerosol Med Pulm Drug Deliv. 2013;26(5):297\u2013306. https:\/\/doi.org\/10.1089\/jamp.2012.0999.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"1213_CR117","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/clpt.2008.184","volume":"85","author":"MJ Avram","year":"2009","unstructured":"Avram MJ, Spyker DA, Henthorn TK, Cassella JV. The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clin Pharmacol Ther. 2009;85(1):71\u20137. https:\/\/doi.org\/10.1038\/clpt.2008.184.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1213_CR118","first-page":"759","volume":"40","author":"JD Lie","year":"2015","unstructured":"Lie JD, Tu KN, Shen DD, Wong BM. Pharmacological treatment of insomnia. P T. 2015;40(11):759\u201371.","journal-title":"P T"},{"issue":"1","key":"1213_CR119","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s13311-021-01010-z","volume":"18","author":"S Madari","year":"2021","unstructured":"Madari S, Golebiowski R, Mansukhani MP, Kolla BP. Pharmacological management of insomnia. Neurotherapeutics. 2021;18(1):44\u201352. https:\/\/doi.org\/10.1007\/s13311-021-01010-z.","journal-title":"Neurotherapeutics"},{"issue":"12","key":"1213_CR120","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/s0149-2918(00)83043-x","volume":"22","author":"D Drover","year":"2000","unstructured":"Drover D, Lemmens H, Naidu S, Cevallos W, Darwish M, Stanski D. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic\/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther. 2000;22(12):1443\u201361. https:\/\/doi.org\/10.1016\/s0149-2918(00)83043-x.","journal-title":"Clin Ther"},{"issue":"5","key":"1213_CR121","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/s0009-9236(98)90139-4","volume":"64","author":"DJ Greenblatt","year":"1998","unstructured":"Greenblatt DJ, Harmatz JS, von Moltke LL, Ehrenberg BL, Harrel L, Corbett K, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther. 1998;64(5):553\u201361. https:\/\/doi.org\/10.1016\/s0009-9236(98)90139-4.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1213_CR122","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40265-020-01307-x","volume":"80","author":"J Paik","year":"2020","unstructured":"Paik J. Levodopa inhalation powder: a review in Parkinson\u2019s disease. Drugs. 2020;80(8):821\u20138. https:\/\/doi.org\/10.1007\/s40265-020-01307-x.","journal-title":"Drugs"},{"issue":"9","key":"1213_CR123","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/mds.26611","volume":"31","author":"PA LeWitt","year":"2016","unstructured":"LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson\u2019s disease. Mov Disord. 2016;31(9):1356\u201365. https:\/\/doi.org\/10.1002\/mds.26611.","journal-title":"Mov Disord"},{"key":"1213_CR124","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.parkreldis.2019.12.012","volume":"71","author":"DG Grosset","year":"2020","unstructured":"Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, et al. Inhaled levodopa in Parkinson\u2019s disease patients with OFF periods: a randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020;71:4\u201310. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.12.012.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"1213_CR125","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/mds.28926","volume":"37","author":"E Thijssen","year":"2022","unstructured":"Thijssen E, den Heijer J, Puibert D, Moss L, Lei M, Hasegawa D, et al. A randomized trial assessing the safety, pharmacokinetics, and efficacy during morning off of AZ-009. Mov Disord. 2022;37(4):790\u20138. https:\/\/doi.org\/10.1002\/mds.28926.","journal-title":"Mov Disord"},{"issue":"5","key":"1213_CR126","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41573-023-00670-0","volume":"22","author":"TH Baryakova","year":"2023","unstructured":"Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023;22(5):387\u2013409. https:\/\/doi.org\/10.1038\/s41573-023-00670-0.","journal-title":"Nat Rev Drug Discov"},{"key":"1213_CR127","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-244x-12-20","volume":"12","author":"M DiBonaventura","year":"2012","unstructured":"DiBonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12:20. https:\/\/doi.org\/10.1186\/1471-244x-12-20.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"1213_CR128","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/13548506.2017.1323108","volume":"23","author":"TR J\u00f8rgensen","year":"2018","unstructured":"J\u00f8rgensen TR, Emborg C, Dahlen K, B\u00f8gelund M, Carlborg A. Patient preferences for medicine administration for acute agitation: results from an internet-based survey of patients diagnosed with bipolar disorder or schizophrenia in two Nordic countries. Psychol Health Med. 2018;23(1):30\u20138. https:\/\/doi.org\/10.1080\/13548506.2017.1323108.","journal-title":"Psychol Health Med"},{"issue":"1","key":"1213_CR129","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1089\/jamp.2011.0895","volume":"25","author":"V Plaza","year":"2012","unstructured":"Plaza V, Sanchis J, Roura P, Molina J, Calle M, Quirce S, et al. Physicians\u2019 knowledge of inhaler devices and inhalation techniques remains poor in Spain. J Aerosol Med Pulm Drug Deliv. 2012;25(1):16\u201322. https:\/\/doi.org\/10.1089\/jamp.2011.0895.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"1213_CR130","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1378\/chest.105.1.111","volume":"105","author":"NA Hanania","year":"1994","unstructured":"Hanania NA, Wittman R, Kesten S, Chapman KR. Medical personnel\u2019s knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest. 1994;105(1):111\u20136. https:\/\/doi.org\/10.1378\/chest.105.1.111.","journal-title":"Chest"},{"issue":"10","key":"1213_CR131","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.4187\/respcare.05501360","volume":"50","author":"JB Fink","year":"2005","unstructured":"Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care. 2005;50(10):1360\u201375.","journal-title":"Respir Care"},{"issue":"4","key":"1213_CR132","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.rmed.2007.11.003","volume":"102","author":"F Lavorini","year":"2008","unstructured":"Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593\u2013604. https:\/\/doi.org\/10.1016\/j.rmed.2007.11.003.","journal-title":"Respir Med"},{"key":"1213_CR133","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/ppa.s395327","volume":"17","author":"J Ma","year":"2023","unstructured":"Ma J, Sun X, Wang X, Liu B, Shi K. Factors affecting patient adherence to inhalation therapy: an application of SEIPS model 2.0. Patient Prefer Adherence. 2023;17:531\u201345. https:\/\/doi.org\/10.2147\/ppa.s395327.","journal-title":"Patient Prefer Adherence"},{"key":"1213_CR134","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.seizure.2017.10.007","volume":"52","author":"M Ga\u00ednza-Lein","year":"2017","unstructured":"Ga\u00ednza-Lein M, Benjamin R, Stredny C, McGurl M, Kapur K, Loddenkemper T. Rescue medications in epilepsy patients: a family perspective. Seizure. 2017;52:188\u201394. https:\/\/doi.org\/10.1016\/j.seizure.2017.10.007.","journal-title":"Seizure"},{"key":"1213_CR135","unstructured":"MannKind Corporation. AFREZZA\u00a0prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022472lbl.pdf. Accessed 2 Dec 2024."},{"issue":"5","key":"1213_CR136","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00213-014-3721-0","volume":"232","author":"CJ Reissig","year":"2015","unstructured":"Reissig CJ, Harrison JA, Carter LP, Griffiths RR. Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Psychopharmacology. 2015;232(5):871\u201383. https:\/\/doi.org\/10.1007\/s00213-014-3721-0.","journal-title":"Psychopharmacology"},{"issue":"5","key":"1213_CR137","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/ftd.0000000000000048","volume":"36","author":"LH Takahashi","year":"2014","unstructured":"Takahashi LH, Huie K, Spyker DA, Fishman RS, Cassella JV. Effect of smoking on the pharmacokinetics of inhaled loxapine. Ther Drug Monit. 2014;36(5):618\u201323. https:\/\/doi.org\/10.1097\/ftd.0000000000000048.","journal-title":"Ther Drug Monit"},{"key":"1213_CR138","unstructured":"Rafa Laboratories Limited. MIDAZOLAM prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/216359s000lbl.pdf. Accessed 2 Dec 2024."},{"issue":"15 Suppl","key":"1213_CR139","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.4437","volume":"94","author":"MA Rogawski","year":"2020","unstructured":"Rogawski MA, Heller AH, Farrow S, Jung C, Klein P, Boudreault S, et al. Pharmacokinetics of diazepam buccal film in adult patients with epilepsy: comparison with diazepam rectal gel (4437). Neurology. 2020;94(15 Suppl): 4437. https:\/\/doi.org\/10.1212\/WNL.94.15_supplement.4437.","journal-title":"Neurology"}],"updated-by":[{"DOI":"10.1007\/s40263-025-01224-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01213-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01213-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01213-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:34:43Z","timestamp":1792085683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01213-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":139,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01213-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"24 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Graphical abstract and the drug names are updated. Video abstract and the slide deck have been included in the original publication.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-025-01224-1","URL":"https:\/\/doi.org\/10.1007\/s40263-025-01224-1","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors received no funding for the development of this work. Medical writing and creative and editorial assistance were provided by Ogilvy Health UK and funded by UCB. The open access fee was paid by UCB.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.D. has received honorarium from Crossject, Neurelis, and UCB for participating in advisory board meetings. AS has received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Neuraxpharm, Takeda, UCB Pharma, and UNEEG Medical. J.C.C. serves as an advisory board member for Neurelis, serves as a consultant for Crossject, and has received research grants from PrevEp and Allaysis. R.R., C.L., and H.C. are employed by UCB.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.D.: conceptualization, writing\u2014review and editing. A.S.: conceptualization, writing\u2014review and editing. R.R.: conceptualization, writing\u2014review and editing. C.L.: conceptualization, writing\u2014review and editing, funding acquisition. H.C.: conceptualization, writing\u2014review and editing. J.C.C.: conceptualization, writing\u2014review and editing. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}